FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
Executive Summary
Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.
You may also be interested in...
Do Ads Noting A Drug’s ‘Targeted’ Mechanism Of Action Impact Perceptions Of the Product?
US FDA will study how presentations of a fictitious cancer drug’s targeted mechanism of action affect consumer and provider interest in the drug and their understanding of its benefits and risks. Another study will assess how consumers and primary care physicians interpret Rx drug names.
Pre-approval Promotion: Corporate Communications May Draw US FDA Scrutiny
Biopharma sponsors should start with information that needs to be disclosed to satisfy SEC rules and understand how a press release will be used to avoid running afoul of agency regulations, industry exec says; company contracts with investigators also should set limits on what they can say about an unapproved drug.
US FDA Reprimands Arog Pharmaceuticals For Promo Of Investigational AML Drug
Third enforcement letter of the year cites meeting exhibit and webpage that suggest crenolanib is safe and effective for an unapproved use.